Welcome to our dedicated page for Akari Therapeutics news (Ticker: AKTX), a resource for investors and traders seeking the latest updates and insights on Akari Therapeutics stock.
Akari Therapeutics plc develops oncology antibody-drug conjugates built around RNA splicing modulator payloads. News about AKTX centers on its ADC platform, the PH1 payload technology, and lead program AKTX-101, a TROP2-targeted ADC studied in solid tumor models including bladder, lung and breast cancer. Updates also cover intellectual-property protection for the company’s payload chemistry and therapeutic applications.
Recurring company developments include preclinical data releases, oncology conference abstracts, strategic development collaborations, capital-structure disclosures, governance matters, and American Depositary Share program updates. As an ADR issuer, Akari’s news may also address ordinary-share and ADS mechanics tied to Nasdaq listing requirements and shareholder approvals.
Akari Therapeutics and Peak Bio have announced a joint portfolio prioritization plan following their merger, focusing on Peak's ADC cancer therapeutic platform technology and Akari's PAS-nomacopan for Geographic Atrophy. The companies aim to secure business development opportunities and funding while advancing these key programs.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.